IAM
CYTK icon

Impax Asset Management’s Cytokinetics CYTK Stock Holding History

Impax Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-28,333
Closed -$328K – 200
2013
Q2 		$328K Buy
+28,333
New +$223K 0.02% 185

Other funds holding CYTK

LPLP
Lansdowne Partners Limited Partnership London, United Kingdom $11.9B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
IIM
Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return

Impax Asset Management's CYTK Position: Q3 2013 in Review

Impax Asset Management sold out of Cytokinetics (CYTK) in Q3 2013, closing a stake of 28,333 shares — an estimated $328K sold.

Impax Asset Management first reported a position in CYTK in Q2 2013 and held it in 1 quarter. The position peaked at $328K in Q2 2013. 101 funds tracked by Wall St. Rank hold CYTK as of Q3 2013.

  • Impax Asset Management reported no remaining Cytokinetics position as of Q3 2013 after selling out during the quarter.
  • Impax Asset Management sold 28,333 Cytokinetics shares in Q3 2013, an estimated $328K.
  • Impax Asset Management first reported a position in Cytokinetics in Q2 2013 and held it in 1 quarter.
  • Impax Asset Management's Cytokinetics position peaked at $328K in Q2 2013.
  • 101 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2013.

Based on Impax Asset Management's 13F filing for Q3 2013, filed 12 Nov 2013.